Boltz-2’s development was led by the Boltz team at MIT under the supervision of Professors Regina Barzilay and Tommi Jaakkola alongside a team of researchers from MIT and Recursion.

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to ...

Boltz-2 is the first biomolecular co-folding model to combine structure and binding affinity prediction, approaching the accuracy of physics-based free energy perturbation (FEP) calculations but ...